These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16472245)

  • 1. Mass spectrometry in drug discovery: a current review.
    Feng WY
    Curr Drug Discov Technol; 2004 Dec; 1(4):295-312. PubMed ID: 16472245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry in drug metabolism and pharmacokinetics: Current trends and future perspectives.
    Cuyckens F
    Rapid Commun Mass Spectrom; 2019 Jul; 33 Suppl 3():90-95. PubMed ID: 30019507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties and in silico ADME modeling in drug discovery.
    Honório KM; Moda TL; Andricopulo AD
    Med Chem; 2013 Mar; 9(2):163-76. PubMed ID: 23016542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hyphenated chromatography-mass spectrometry techniques in exploratory drug metabolism and pharmacokinetics.
    Hsieh Y; Korfmacher W
    Curr Pharm Des; 2009; 15(19):2251-61. PubMed ID: 19601826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.
    Balani SK; Miwa GT; Gan LS; Wu JT; Lee FW
    Curr Top Med Chem; 2005; 5(11):1033-8. PubMed ID: 16181128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in predicting human ADME parameters in silico.
    Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
    J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on bioanalytical mass spectrometry and automation in drug discovery.
    Janiszewski JS; Liston TE; Cole MJ
    Curr Drug Metab; 2008 Nov; 9(9):986-94. PubMed ID: 18991596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Current Use of Mass Spectrometry in Combination with Oth er Separation Techniques in Drug Discovery Arena.
    Kawczak P; Baczek T
    Med Chem; 2016; 12(5):404-11. PubMed ID: 26732114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of mass spectrometry in early stages of target based drug discovery.
    Deng G; Sanyal G
    J Pharm Biomed Anal; 2006 Feb; 40(3):528-38. PubMed ID: 16256286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical applications of mass spectrometry in pharmaceutical drug discovery.
    Geoghegan KF; Kelly MA
    Mass Spectrom Rev; 2005; 24(3):347-66. PubMed ID: 15389851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry analysis of new chemical entities for pharmaceutical discovery.
    Fang AS; Miao X; Tidswell PW; Towle MH; Goetzinger WK; Kyranos JN
    Mass Spectrom Rev; 2008; 27(1):20-34. PubMed ID: 18033735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening for lead optimization: a rational approach.
    Bajpai M; Adkison KK
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):63-71. PubMed ID: 19649839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical applications of affinity-ultrafiltration mass spectrometry: Recent advances and future prospects.
    Wei H; Zhang X; Tian X; Wu G
    J Pharm Biomed Anal; 2016 Nov; 131():444-453. PubMed ID: 27668554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.